Beatriz Cardeñes

Beatriz Cardeñes

Auto-generated profile, based on publicly available information

Beatriz Cardeñes

Departamento de Biología Celular e Inmunología, Centro de Biología Molecular Severo Ochoa (CSIC-UAM), Madrid, Spain

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
RRRaquel Reyes
Raquel Reyes
BCBeatriz Cardeñes
Beatriz Cardeñes
YMYesenia Machado-Pineda
Yesenia Machado-Pineda
Carlos CabañasCarlos Cabañas
Carlos Cabañas
The tetraspanin CD9 is expressed by all the major subsets of leukocytes (B cells, CD4+ T cells, CD8+ T cells, natural killer cells, granulocytes, monocytes and macrophages, and immature and mature dendritic cells) and also at a high level by endothelial cells. As a typical member of the tetraspanin superfamily, a prominent feature of CD9 is its propensity to engage in a multitude of interactions with other tetraspanins as well as with different transmembrane and intracellular proteins within the context of defined membranal domains termed tetraspanin-enriched microdomains (TEMs). Through these associations, CD9 influences many cellular activities in the different subtypes of leukocytes and in endothelial cells, including intracellular signaling, proliferation, activation, survival, migration, invasion, adhesion, and diapedesis. Several excellent reviews have already covered the topic of how tetraspanins, including CD9, regulate these cellular processes in the different cells of the immune system. In this mini-review, however, we will focus particularly on describing and discussing the regulatory effects exerted by CD9 on different adhesion molecules that play pivotal roles in the physiology of leukocytes and endothelial cells, with a particular emphasis in the regulation of adhesion molecules of the integrin and immunoglobulin superfamilies.

19 July 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
VTVíctor Toribio
Víctor Toribio
SMSara Morales
Sara Morales
SLSoraya López-Martín
Soraya López-Martín
BCBeatriz Cardeñes
Beatriz Cardeñes
Carlos CabañasCarlos Cabañas
Carlos Cabañas
María Yáñez-MoMaría Yáñez-Mo
María Yáñez-Mo
The outstanding potential of Extracellular Vesicles (EVs) in medicine, deserves a detailed study of the molecular aspects regulating their incorporation into target cells. However, because EV size lies below the limit of resolution of optical techniques, quantification together with discrimination between EV binding to the target cell and uptake is usually not completely achieved with current techniques. Human tetraspanins CD9 and CD63 were fused to a dual EGFP-Renilla-split tag. Subcellular localization and incorporation of these fusion proteins into EVs was assessed by western-blot and fluorescence microscopy. EV binding and uptake was measured using either a classical Renilla substrate or a cytopermeable one. Incubation of target cells expressing DSP2 with EVs containing the complementary DSP1 portion could not recover fluorescence or luciferase activity. However, using EVs carrying the fully reconstituted Dual-EGFP-Renilla protein and the cytopermeable Renilla luciferase substrate, we could distinguish EV binding from uptake. We provide proof of concept of the system by analysing the effect of different chemical inhibitors, demonstrating that this method is highly sensitive and quantitative, allowing a dynamic follow-up in a high-throughput scheme to unravel the molecular mechanisms of EV uptake in different biological systems.

1 October 2015 in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
Verified
Journal Article
Closed access
RRRaquel Reyes-Manzanas
Raquel Reyes-Manzanas
AMAlicia Monjas
Alicia Monjas
MYMaría Yánez-Mó
María Yánez-Mó
BCBeatriz Cardeñes
Beatriz Cardeñes
GMGiulia Morlino
Giulia Morlino
Carlos CabañasCarlos Cabañas
Carlos Cabañas

5 November 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
YMYesenia Machado-Pineda
Yesenia Machado-Pineda
BCBeatriz Cardeñes
Beatriz Cardeñes
RRRaquel Reyes
Raquel Reyes
SLSoraya López-Martín
Soraya López-Martín
VTVíctor Toribio
Víctor Toribio
Carlos CabañasCarlos Cabañas
Carlos Cabañas
Integrin α5β1 is a crucial adhesion molecule that mediates the adherence of many cell types to the extracellular matrix through recognition of its classic ligand fibronectin as well as to other cells through binding to an alternative counter-receptor, the metalloproteinase ADAM17/TACE. Interactions between integrin α5β1 and ADAM17 may take place both in trans (between molecules expressed on different cells) or in cis (between molecules expressed on the same cell) configurations. It has been recently reported that the cis association between α5β1 and ADAM17 keeps both molecules inactive, whereas their dissociation results in activation of their adhesive and metalloproteinase activities. Here we show that the tetraspanin CD9 negatively regulates integrin α5β1-mediated cell adhesion by enhancing the cis interaction of this integrin with ADAM17 on the cell surface. Additionally we show that, similarly to CD9, the monoclonal antibody 2A10 directed to the disintegrin domain of ADAM17 specifically inhibits integrin α5β1-mediated cell adhesion to its ligands fibronectin and ADAM17.

27 September 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
ATAlvaro Torres-Gomez
Alvaro Torres-Gomez
TATara Fiyouzi Alipour
Tara Fiyouzi Alipour
CGClaudia Guerra-Espinosa
Claudia Guerra-Espinosa
BCBeatriz Cardeñes
Beatriz Cardeñes
ICIrene Clares
Irene Clares
ESTHER M LAFUENTEESTHER M LAFUENTE
ESTHER M LAFUENTE
Activation of the integrin phagocytic receptors CR3 (αMβ2, CD11b/CD18) and CR4 (αXβ2, CD11c/CD18) requires Rap1 activation and RIAM function. RIAM controls integrin activation by recruiting Talin to β2subunits, enabling the Talin-Vinculin interaction, which in term bridges integrins to the actin-cytoskeleton. RIAM also recruits VASP to phagocytic cups and facilitates VASP phosphorylation and function promoting particle internalization. Using a CRISPR-Cas9 knockout approach, we have analyzed the requirement for RIAM, VASP and Vinculin expression in neutrophilic-HL-60 cells. All knockout cells displayed abolished phagocytosis that was accompanied by a significant and specific reduction in ITGAM (αM), ITGAX (αX) and ITGB2 (β2) mRNA, as revealed by RT-qPCR. RIAM, VASP and Vinculin KOs presented reduced cellular F-actin content that correlated with αM expression, as treatment with the actin filament polymerizing and stabilizing drug jasplakinolide, partially restored αMexpression. In general, the expression of αXwas less responsive to jasplakinolide treatment than αM, indicating that regulatory mechanisms independent of F-actin content may be involved. The Serum Response Factor (SRF) was investigated as the potential transcription factor controlling αMβ2expression, since its coactivator MRTF-A requires actin polymerization to induce transcription. Immunofluorescent MRTF-A localization in parental cells was primarily nuclear, while in knockouts it exhibited a diffuse cytoplasmic pattern. Localization of FHL-2 (SRF corepressor) was mainly sub-membranous in parental HL-60 cells, but in knockouts the localization was disperse in the cytoplasm and the nucleus, suggesting RIAM, VASP and Vinculin are required to maintain FHL-2 close to cytoplasmic membranes, reducing its nuclear localization and inhibiting its corepressor activity. Finally, reexpression of VASP in the VASP knockout resulted in a complete reversion of the phenotype, as knock-ins restored αMexpression. Taken together, our results suggest that RIAM, VASP and Vinculin, are necessary for the correct expression of αMβ2and αXβ2during neutrophilic differentiation in the human promyelocytic HL-60 cell line, and strongly point to an involvement of these proteins in the acquisition of a phagocytic phenotype.